{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:24:14Z","timestamp":1793967854655,"version":"4.8.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573833"],"award-info":[{"award-number":["82573833"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303091"],"award-info":[{"award-number":["82303091"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["JCYJ20250604180129038"],"award-info":[{"award-number":["JCYJ20250604180129038"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M753095"],"award-info":[{"award-number":["2024M753095"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Abnormal accumulation of Poly(ADP-ribose) polymerase 1 (PARP1) promotes cancer progression, yet its stabilization mechanisms remain unclear. Here, we identify E3 ubiquitin ligase tripartite motif-containing 21 (TRIM21) as a PARP1-binding partner. PARP1 interacts directly with TRIM21 via its 662-908 domain, while the PRY-SPRY domain of TRIM21 is essential for this binding. TRIM21 facilitates PARP1 polyubiquitination at residue K654, leading to its degradation. In small cell lung cancer (SCLC), TRIM21 is significantly downregulated, and its tumor-suppressive function is partly mediated through the degradation of PARP1, supporting genomic stability. Additionally, the PI3K\/AKT pathway transcriptionally suppresses TRIM21 via transcription factor STAT5A, thereby stabilizing PARP1. Importantly, combining the PI3K\/AKT inhibitor PKI-587 with the PARP inhibitor BMN673 synergistically inhibits tumor growth across multiple SCLC models, including cell lines, patient-derived organoids, and xenograft models. Collectively, our findings define a \u201cPI3K\/AKT-STAT5A-TRIM21-PARP1\u201d axis critical for SCLC progression and propose its dual inhibition as a promising therapeutic strategy.<\/jats:p>","DOI":"10.1038\/s41467-026-73271-1","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:52:54Z","timestamp":1781776374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TRIM21-mediated ubiquitination of PARP1 regulated by the PI3K\/AKT-STAT5A axis suppresses small cell lung cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0213-7153","authenticated-orcid":false,"given":"Guozhen","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8488-1053","authenticated-orcid":false,"given":"Gongfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9171-4073","authenticated-orcid":false,"given":"Xiaolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhuang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-0289","authenticated-orcid":false,"given":"Jiahui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-0588","authenticated-orcid":false,"given":"Li","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-6390","authenticated-orcid":false,"given":"Hongbin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2346-9808","authenticated-orcid":false,"given":"Chenchen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-1725","authenticated-orcid":false,"given":"Wenchu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"73271_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nrc.2017.87","volume":"17","author":"AF Gazdar","year":"2017","unstructured":"Gazdar, A. F., Bunn, P. A. & Minna, J. D. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat. Rev. Cancer 17, 725\u2013737 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"73271_CR2","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/s12276-022-00905-x","volume":"54","author":"NA Kirk","year":"2022","unstructured":"Kirk, N. A., Kim, K. B. & Park, K. S. Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer. Exp. Mol. Med. 54, 2118\u20132127 (2022).","journal-title":"Exp. Mol. Med."},{"key":"73271_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2020.11.006","volume":"83","author":"P Khan","year":"2022","unstructured":"Khan, P. et al. Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Semin Cancer Biol. 83, 57\u201376 (2022).","journal-title":"Semin Cancer Biol."},{"key":"73271_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri, A. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18, 610\u2013621 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"73271_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.cell.2024.01.015","volume":"187","author":"N Chappidi","year":"2024","unstructured":"Chappidi, N. et al. PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends. Cell 187, 945\u2013961.e18 (2024).","journal-title":"Cell"},{"key":"73271_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.redox.2018.03.016","volume":"17","author":"D Hou","year":"2018","unstructured":"Hou, D. et al. Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer. Redox Biol. 17, 99\u2013111 (2018).","journal-title":"Redox Biol."},{"key":"73271_CR7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","volume":"2","author":"LA Byers","year":"2012","unstructured":"Byers, L. A. et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2, 798\u2013811 (2012).","journal-title":"Cancer Discov."},{"key":"73271_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2021.01.008","volume":"503","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. Cancer Lett. 503, 197\u2013212 (2021).","journal-title":"Cancer Lett."},{"key":"73271_CR9","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-13-0010","volume":"12","author":"JP Chow","year":"2013","unstructured":"Chow, J. P. et al. PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. Mol. Cancer Ther. 12, 2517\u20132528 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"73271_CR10","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s43018-023-00535-w","volume":"4","author":"X Sun","year":"2023","unstructured":"Sun, X. et al. Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. Nat. Cancer 4, 716\u2013733 (2023).","journal-title":"Nat. Cancer"},{"key":"73271_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.804962","volume":"9","author":"F Wang","year":"2021","unstructured":"Wang, F., Gouttia, O. G., Wang, L. & Peng, A. PARP1 Upregulation in Recurrent Oral Cancer and Treatment Resistance. Front. Cell Dev. Biol. 9, 804962 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"73271_CR12","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/emboj.2009.279","volume":"28","author":"N Martin","year":"2009","unstructured":"Martin, N. et al. PARP-1 transcriptional activity is regulated by sumoylation upon heat shock. EMBO J. 28, 3534\u20133548 (2009).","journal-title":"EMBO J."},{"key":"73271_CR13","doi-asserted-by":"publisher","first-page":"12975","DOI":"10.1074\/jbc.M111.321828","volume":"287","author":"L Kashima","year":"2012","unstructured":"Kashima, L. et al. CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation. J. Biol. Chem. 287, 12975\u201312984 (2012).","journal-title":"J. Biol. Chem."},{"key":"73271_CR14","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/nar\/gks1278","volume":"41","author":"C Liu","year":"2013","unstructured":"Liu, C., Wu, J., Paudyal, S. C., You, Z. & Yu, X. CHFR is important for the first wave of ubiquitination at DNA damage sites. Nucleic Acids Res. 41, 1698\u20131710 (2013).","journal-title":"Nucleic Acids Res."},{"key":"73271_CR15","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1111\/jcmm.15121","volume":"24","author":"H Qian","year":"2020","unstructured":"Qian, H. et al. The E3 ubiquitin ligase Smurf2 regulates PARP1 stability to alleviate oxidative stress-induced injury in human umbilical vein endothelial cells. J. Cell Mol. Med. 24, 4600\u20134611 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"73271_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/imr.12363","volume":"268","author":"S Foss","year":"2015","unstructured":"Foss, S., Watkinson, R., Sandlie, I., James, L. C. & Andersen, J. T. TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol. Rev. 268, 328\u2013339 (2015).","journal-title":"Immunol. Rev."},{"key":"73271_CR17","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.cmet.2023.05.011","volume":"35","author":"X Lu","year":"2023","unstructured":"Lu, X. et al. UBE2M-mediated neddylation of TRIM21 regulates obesity-induced inflammation and metabolic disorders. Cell Metab. 35, 1390\u20131405.e1398 (2023).","journal-title":"Cell Metab."},{"key":"73271_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/ni.2492","volume":"14","author":"Z Zhang","year":"2013","unstructured":"Zhang, Z. et al. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat. Immunol. 14, 172\u2013178 (2013).","journal-title":"Nat. Immunol."},{"key":"73271_CR19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41388-025-03288-1","volume":"44","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. Phospho-TRIM21 orchestrates RPA2 ubiquitination switch to promote homologous recombination and tumor radio\/chemo-resistance. Oncogene 44, 1106\u20131117 (2025).","journal-title":"Oncogene"},{"key":"73271_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ijbiomac.2018.11.269","volume":"124","author":"Y Jin","year":"2019","unstructured":"Jin, Y. et al. TRIM21 mediates ubiquitination of Snail and modulates epithelial to mesenchymal transition in breast cancer cells. Int. J. Biol. Macromol. 124, 846\u2013853 (2019).","journal-title":"Int. J. Biol. Macromol."},{"key":"73271_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/joim.12375","volume":"278","author":"S Brauner","year":"2015","unstructured":"Brauner, S. et al. Reduced expression of TRIM21\/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. J. Intern Med 278, 323\u2013332 (2015).","journal-title":"J. Intern Med"},{"key":"73271_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2021.03.023","volume":"508","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. Trim21-mediated HIF-1alpha degradation attenuates aerobic glycolysis to inhibit renal cancer tumorigenesis and metastasis. Cancer Lett. 508, 115\u2013126 (2021).","journal-title":"Cancer Lett."},{"key":"73271_CR23","first-page":"114","volume":"10","author":"Z Zhao","year":"2020","unstructured":"Zhao, Z. et al. TRIM21 overexpression promotes tumor progression by regulating cell proliferation, cell migration and cell senescence in human glioma. Am. J. Cancer Res 10, 114\u2013130 (2020).","journal-title":"Am. J. Cancer Res"},{"key":"73271_CR24","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jcmgh.2021.01.007","volume":"11","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. The ubiquitin E3 ligase TRIM21 promotes hepatocarcinogenesis by suppressing the p62-Keap1-Nrf2 antioxidant pathway. Cell Mol. Gastroenterol. Hepatol. 11, 1369\u20131385 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"73271_CR25","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.1073\/pnas.0609174104","volume":"104","author":"LC James","year":"2007","unstructured":"James, L. C., Keeble, A. H., Khan, Z., Rhodes, D. A. & Trowsdale, J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc. Natl. Acad. Sci. USA 104, 6200\u20136205 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73271_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.molcel.2016.02.007","volume":"61","author":"JA Pan","year":"2016","unstructured":"Pan, J. A. et al. TRIM21 ubiquitylates SQSTM1\/p62 and suppresses protein sequestration to regulate redox homeostasis. Mol. Cell 61, 720\u2013733 (2016).","journal-title":"Mol. Cell"},{"key":"73271_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbrc.2005.11.029","volume":"339","author":"K Wada","year":"2006","unstructured":"Wada, K. & Kamitani, T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem. Biophys. Res. Commun. 339, 415\u2013421 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"73271_CR28","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1158\/0008-5472.CAN-24-4245","volume":"85","author":"G Cao","year":"2025","unstructured":"Cao, G. et al. Interaction and reciprocal stabilization of H3.3 and PARP1 promote DNA damage repair and tumor progression in small cell lung cancer. Cancer Res. 85, 4918\u20134936 (2025).","journal-title":"Cancer Res."},{"key":"73271_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105443","volume":"165","author":"M Alomari","year":"2021","unstructured":"Alomari, M. TRIM21 - A potential novel therapeutic target in cancer. Pharm. Res. 165, 105443 (2021).","journal-title":"Pharm. Res."},{"key":"73271_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","volume":"23","author":"Y-J Li","year":"2023","unstructured":"Li, Y.-J., Zhang, C., Martincuks, A., Herrmann, A. & Yu, H. STAT proteins in cancer: orchestration of metabolism. Nat. Rev. Cancer 23, 115\u2013134 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"73271_CR31","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1158\/1078-0432.CCR-17-2768","volume":"24","author":"C Maranto","year":"2018","unstructured":"Maranto, C. et al. STAT5A\/B blockade sensitizes prostate cancer to radiation through inhibition of RAD51 and DNA repair. Clin. Cancer Res. 24, 1917\u20131931 (2018).","journal-title":"Clin. Cancer Res."},{"key":"73271_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/1078-0432.CCR-12-1138","volume":"19","author":"A Wojtalla","year":"2013","unstructured":"Wojtalla, A. et al. Targeting the phosphoinositide 3-kinase p110-alpha isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer. Clin. Cancer Res. 19, 96\u2013105 (2013).","journal-title":"Clin. Cancer Res."},{"key":"73271_CR33","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1158\/1078-0432.CCR-13-1975","volume":"19","author":"RJ Cardnell","year":"2013","unstructured":"Cardnell, R. J. et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin. Cancer Res. 19, 6322\u20136328 (2013).","journal-title":"Clin. Cancer Res."},{"key":"73271_CR34","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias, M. P., Moser, S. C., Ganesan, S. & Jonkers, J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 18, 773\u2013791 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"73271_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li, H. et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol. Cancer 19, 107 (2020).","journal-title":"Mol. Cancer"},{"key":"73271_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.261","volume":"4","author":"Q Zhong","year":"2023","unstructured":"Zhong, Q. et al. Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications. MedComm (2020) 4, e261 (2023).","journal-title":"MedComm (2020)"},{"key":"73271_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35795-8","volume":"14","author":"JM Lee","year":"2023","unstructured":"Lee, J. M., Hammaren, H. M., Savitski, M. M. & Baek, S. H. Control of protein stability by post-translational modifications. Nat. Commun. 14, 201 (2023).","journal-title":"Nat. Commun."},{"key":"73271_CR38","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41580-021-00448-5","volume":"23","author":"DA Cruz Walma","year":"2022","unstructured":"Cruz Walma, D. A., Chen, Z., Bullock, A. N. & Yamada, K. M. Ubiquitin ligases: guardians of mammalian development. Nat. Rev. Mol. Cell Biol. 23, 350\u2013367 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"73271_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","volume":"5","author":"L Deng","year":"2020","unstructured":"Deng, L., Meng, T., Chen, L., Wei, W. & Wang, P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct. Target Ther. 5, 11 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"73271_CR40","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.kint.2022.05.026","volume":"102","author":"JT Yu","year":"2022","unstructured":"Yu, J. T. et al. Insulin-like growth factor binding protein 7 promotes acute kidney injury by alleviating poly ADP ribose polymerase 1 degradation. Kidney Int 102, 828\u2013844 (2022).","journal-title":"Kidney Int"},{"key":"73271_CR41","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/s41418-020-0523-2","volume":"27","author":"N Zhang","year":"2020","unstructured":"Zhang, N. et al. Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling. Cell Death Differ. 27, 2605\u20132619 (2020).","journal-title":"Cell Death Differ."},{"key":"73271_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41421-023-00555-x","volume":"9","author":"N Zhang","year":"2023","unstructured":"Zhang, N. et al. BAF155 promotes cardiac hypertrophy and fibrosis through inhibition of WWP2-mediated PARP1 ubiquitination. Cell Discov. 9, 46 (2023).","journal-title":"Cell Discov."},{"key":"73271_CR43","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/s41416-022-01970-9","volume":"127","author":"G Zhang","year":"2022","unstructured":"Zhang, G. et al. HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway. Br. J. Cancer 127, 1925\u20131938 (2022).","journal-title":"Br. J. Cancer"},{"key":"73271_CR44","doi-asserted-by":"publisher","first-page":"14103","DOI":"10.1073\/pnas.1108799108","volume":"108","author":"HC Kang","year":"2011","unstructured":"Kang, H. C. et al. Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. Proc. Natl. Acad. Sci. USA 108, 14103\u201314108 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73271_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102141","volume":"47","author":"N Zhang","year":"2021","unstructured":"Zhang, N. et al. Deacetylation-dependent regulation of PARP1 by SIRT2 dictates ubiquitination of PARP1 in oxidative stress-induced vascular injury. Redox Biol. 47, 102141 (2021).","journal-title":"Redox Biol."},{"key":"73271_CR46","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s12276-025-01490-5","volume":"57","author":"DS Kim","year":"2025","unstructured":"Kim, D. S., Park, Y., Tsokos, G. C., Cho, M.-L. & Kwok, S.-K. The ubiquitin E3 ligase TRIM21 suppresses type I interferon signaling via STING degradation and ameliorates systemic autoimmunity. Exp. Mol. Med. 57, 1555\u20131566 (2025).","journal-title":"Exp. Mol. Med."},{"key":"73271_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112125","volume":"42","author":"TET Mevissen","year":"2023","unstructured":"Mevissen, T. E. T., Prasad, A. V. & Walter, J. C. TRIM21-dependent target protein ubiquitination mediates cell-free Trim-Away. Cell Rep. 42, 112125 (2023).","journal-title":"Cell Rep."},{"key":"73271_CR48","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nrc3139","volume":"11","author":"S Hatakeyama","year":"2011","unstructured":"Hatakeyama, S. TRIM proteins and cancer. Nat. Rev. Cancer 11, 792\u2013804 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"73271_CR49","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/nar\/gkac011","volume":"50","author":"X Zhu","year":"2022","unstructured":"Zhu, X. et al. TRIM21 suppresses CHK1 activation by preferentially targeting CLASPIN for K63-linked ubiquitination. Nucleic Acids Res. 50, 1517\u20131530 (2022).","journal-title":"Nucleic Acids Res."},{"key":"73271_CR50","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jhep.2025.03.035","volume":"83","author":"T Cui","year":"2025","unstructured":"Cui, T. et al. Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response. J. Hepatol. 83, 946\u2013958 (2025).","journal-title":"J. Hepatol."},{"key":"73271_CR51","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1083\/jcb.201503023","volume":"210","author":"T Kimura","year":"2015","unstructured":"Kimura, T. et al. TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity. J. Cell Biol. 210, 973\u2013989 (2015).","journal-title":"J. Cell Biol."},{"key":"73271_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40164-022-00322-w","volume":"11","author":"N Huang","year":"2022","unstructured":"Huang, N. et al. TRIM family contribute to tumorigenesis, cancer development, and drug resistance. Exp. Hematol. Oncol. 11, 75 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"73271_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15819-3","volume":"11","author":"J Cheng","year":"2020","unstructured":"Cheng, J. et al. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K\/AKT pathway and PPP metabolism. Nat. Commun. 11, 1880 (2020).","journal-title":"Nat. Commun."},{"key":"73271_CR54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mce.2017.04.025","volume":"451","author":"PD Radler","year":"2017","unstructured":"Radler, P. D., Wehde, B. L. & Wagner, K. U. Crosstalk between STAT5 activation and PI3K\/AKT functions in normal and transformed mammary epithelial cells. Mol. Cell Endocrinol. 451, 31\u201339 (2017).","journal-title":"Mol. Cell Endocrinol."},{"key":"73271_CR55","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1128\/MCB.01220-13","volume":"34","author":"JW Schmidt","year":"2014","unstructured":"Schmidt, J. W. et al. Stat5 regulates the phosphatidylinositol 3-kinase\/Akt1 pathway during mammary gland development and tumorigenesis. Mol. Cell Biol. 34, 1363\u20131377 (2014).","journal-title":"Mol. Cell Biol."},{"key":"73271_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","volume":"60","author":"Y Verhoeven","year":"2020","unstructured":"Verhoeven, Y. et al. The potential and controversy of targeting STAT family members in cancer. Semin. Cancer Biol. 60, 41\u201356 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"73271_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50925-6","volume":"15","author":"JX Lin","year":"2024","unstructured":"Lin, J. X. et al. Tyrosine phosphorylation of both STAT5A and STAT5B is necessary for maximal IL-2 signaling and T cell proliferation. Nat. Commun. 15, 7372 (2024).","journal-title":"Nat. Commun."},{"key":"73271_CR58","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips, R. L. et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell 185, 3857\u20133876 (2022).","journal-title":"Cell"},{"key":"73271_CR59","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 425 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"73271_CR60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj, G. & Manning, B. D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer 20, 74\u201388 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"73271_CR61","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41401-022-00994-4","volume":"44","author":"GZ Cao","year":"2023","unstructured":"Cao, G. Z. et al. Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors. Acta Pharm. Sin. 44, 841\u2013852 (2023).","journal-title":"Acta Pharm. Sin."},{"key":"73271_CR62","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.molcel.2022.02.021","volume":"82","author":"D Huang","year":"2022","unstructured":"Huang, D. & Kraus, W. L. The expanding universe of PARP1-mediated molecular and therapeutic mechanisms. Mol. Cell 82, 2315\u20132334 (2022).","journal-title":"Mol. Cell"},{"key":"73271_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47\u201353 (2015).","journal-title":"Nature"},{"key":"73271_CR64","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-20-4259","volume":"27","author":"LA Byers","year":"2021","unstructured":"Byers, L. A. et al. Veliparib in combination with carboplatin and etoposide in patients with treatment-naive extensive-stage small cell lung cancer: a phase 2 randomized study. Clin. Cancer Res. 27, 3884\u20133895 (2021).","journal-title":"Clin. Cancer Res."},{"key":"73271_CR65","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim, Y. H. et al. PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2, 1036\u20131047 (2012).","journal-title":"Cancer Discov."},{"key":"73271_CR66","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/onc.2017.326","volume":"37","author":"X Bian","year":"2018","unstructured":"Bian, X. et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37, 341\u2013351 (2018).","journal-title":"Oncogene"},{"key":"73271_CR67","doi-asserted-by":"publisher","first-page":"e0152584","DOI":"10.1371\/journal.pone.0152584","volume":"11","author":"RJ Cardnell","year":"2016","unstructured":"Cardnell, R. J. et al. Activation of the PI3K\/mTOR pathway following PARP inhibition in small cell lung cancer. PLoS One 11, e0152584 (2016).","journal-title":"PLoS One"},{"key":"73271_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00588-1","volume":"9","author":"N Huang","year":"2023","unstructured":"Huang, N. et al. TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC. NPJ Breast Cancer 9, 85 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"73271_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42546-2","volume":"14","author":"A Fletcher","year":"2023","unstructured":"Fletcher, A. et al. A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation. Nat. Commun. 14, 7093 (2023).","journal-title":"Nat. Commun."},{"key":"73271_CR70","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.tibs.2021.01.014","volume":"46","author":"N Pandey","year":"2021","unstructured":"Pandey, N. & Black, B. E. Rapid detection and signaling of DNA damage by PARP-1. Trends Biochem Sci. 46, 744\u2013757 (2021).","journal-title":"Trends Biochem Sci."},{"key":"73271_CR71","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nrd3868","volume":"11","author":"JL Riffell","year":"2012","unstructured":"Riffell, J. L., Lord, C. J. & Ashworth, A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov. 11, 923\u2013936 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73271_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36523-y","volume":"14","author":"JY Li","year":"2023","unstructured":"Li, J. Y. et al. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models. Nat. Commun. 14, 865 (2023).","journal-title":"Nat. Commun."},{"key":"73271_CR73","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201847528","volume":"21","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. TRIM21-mediated proteasomal degradation of SAMHD1 regulates its antiviral activity. EMBO Rep. 21, e47528 (2020).","journal-title":"EMBO Rep."},{"key":"73271_CR74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406936121","volume":"121","author":"WL Ye","year":"2024","unstructured":"Ye, W. L. et al. TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer. Proc. Natl. Acad. Sci. USA 121, e2406936121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73271_CR75","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/15548627.2022.2164427","volume":"19","author":"C Yang","year":"2023","unstructured":"Yang, C. et al. Stress granule homeostasis is modulated by TRIM21-mediated ubiquitination of G3BP1 and autophagy-dependent elimination of stress granules. Autophagy 19, 1934\u20131951 (2023).","journal-title":"Autophagy"},{"key":"73271_CR76","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1038\/s41596-021-00615-0","volume":"16","author":"N Brix","year":"2021","unstructured":"Brix, N., Samaga, D., Belka, C., Zitzelsberger, H. & Lauber, K. Analysis of clonogenic growth in vitro. Nat. Protoc. 16, 4963\u20134991 (2021).","journal-title":"Nat. Protoc."},{"key":"73271_CR77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2012881118","volume":"118","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. CircURI1 interacts with hnRNPM to inhibit metastasis by modulating alternative splicing in gastric cancer. Proc. Natl. Acad. Sci. USA 118, e2012881118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73271_CR78","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1016\/j.molcel.2024.10.001","volume":"84","author":"Q Li","year":"2024","unstructured":"Li, Q. et al. ZC3H14 facilitates backsplicing by binding to exon-intron boundary and 3\u2019 UTR. Mol. Cell 84, 4314\u20134333.e19 (2024).","journal-title":"Mol. Cell"},{"key":"73271_CR79","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41556-023-01123-x","volume":"25","author":"G Yan","year":"2023","unstructured":"Yan, G. et al. Genome-wide CRISPR screens identify ILF3 as a mediator of mTORC1-dependent amino acid sensing. Nat. Cell Biol. 25, 754\u2013764 (2023).","journal-title":"Nat. Cell Biol."},{"key":"73271_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107985","volume":"32","author":"M Gatti","year":"2020","unstructured":"Gatti, M., Imhof, R., Huang, Q., Baudis, M. & Altmeyer, M. The ubiquitin ligase TRIP12 Limits PARP1 trapping and constrains PARP inhibitor efficiency. Cell Rep. 32, 107985 (2020).","journal-title":"Cell Rep."},{"key":"73271_CR81","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1093\/nar\/gkz058","volume":"47","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. The WD40 domain of FBXW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response. Nucleic Acids Res. 47, 4039\u20134053 (2019).","journal-title":"Nucleic Acids Res."},{"key":"73271_CR82","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41556-021-00807-6","volume":"24","author":"DB Krastev","year":"2022","unstructured":"Krastev, D. B. et al. The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nat. Cell Biol. 24, 62\u201373 (2022).","journal-title":"Nat. Cell Biol."},{"key":"73271_CR83","doi-asserted-by":"publisher","DOI":"10.34133\/research.0908","volume":"8","author":"G Cao","year":"2025","unstructured":"Cao, G. et al. ARID1A governs genomic stability and proliferation in SCLC via c-MYC\/PARP1 suppression driving vulnerability to BET inhibitors. Research 8, 0908 (2025).","journal-title":"Research"},{"key":"73271_CR84","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli, G. Y. et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32, 2866\u20132868 (2016).","journal-title":"Bioinformatics"},{"key":"73271_CR85","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136779","volume":"131","author":"J Cho","year":"2021","unstructured":"Cho, J. et al. RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. J. Clin. Invest 131, e136779 (2021).","journal-title":"J. Clin. Invest"},{"key":"73271_CR86","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1038\/s41418-021-00801-3","volume":"28","author":"S Dasgupta","year":"2021","unstructured":"Dasgupta, S. et al. RGS5\u2013TGF\u03b2\u2013Smad2\/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth. Cell Death Differ. 28, 3052\u20133076 (2021).","journal-title":"Cell Death Differ."},{"key":"73271_CR87","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf0854","volume":"9","author":"Y Xiang","year":"2023","unstructured":"Xiang, Y. et al. Ultrasound-triggered interfacial engineering-based microneedle for bacterial infection acne treatment. Sci. Adv. 9, eadf0854 (2023).","journal-title":"Sci. Adv."},{"key":"73271_CR88","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1186\/s13071-015-1248-9","volume":"8","author":"W Chen","year":"2015","unstructured":"Chen, W. et al. Identification and characterization of Clonorchis sinensis cathepsin B proteases in the pathogenesis of clonorchiasis. Parasit. Vectors 8, 647 (2015).","journal-title":"Parasit. Vectors"},{"key":"73271_CR89","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s43018-022-00358-1","volume":"3","author":"C Guo","year":"2022","unstructured":"Guo, C. et al. Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. Nat. Cancer 3, 614\u2013628 (2022).","journal-title":"Nat. Cancer"},{"key":"73271_CR90","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell 187, 184\u2013203.e28 (2024).","journal-title":"Cell"},{"key":"73271_CR91","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","volume":"42","author":"X Tong","year":"2024","unstructured":"Tong, X. et al. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer Cell 42, 413\u2013428.e7 (2024).","journal-title":"Cancer Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73271-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73271-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73271-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:04:04Z","timestamp":1785801844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73271-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73271"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73271-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7704"}}